Allecra Therapeutics GmbH
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Allecra Therapeutics GmbH
Concizumab, Elranatamab & Talquetamab Among New EU Filings At EMA
The European Medicines Agency has started reviewing a new batch of medicines for potential pan-EU marketing approval.
Allecra Seeks US Partnership For Urinary Tract Asset As Regulatory Filings Approach
The French firm is searching for a US partner with strong foundations in the hospital sector after securing EU and China deals for its complicated urinary tract infection candidate that combines cefepime and enmetazobactam, which is nearing regulatory submission in key markets.
Deal Watch: How Did J.P. Morgan Deal-Making Compare To Prior Years?
Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.
Pipeline Watch: Phase III Starts With Murepavadin, CSL112 And Vibegron
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.